BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Result of Assessment of Small molecule Protein-Protein Interaction (PPI) Inhibitors Designed by Interprotein


11/28/2012 12:39:34 PM

November, 2012 -- Interprotein Corporation (President, Masato HOSODA; Headquarters: Osaka, Japan; hereinafter “Interprotein”) today announced the result of assessment of small molecule PPI inhibitors that were designed by INTENDD (Interprotein’s Engine for New Drug Design), a platform technology of Interprotein, under the collaborative research between Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan; hereinafter “Takeda”) and Interprotein.

The compounds designed by Interprotein were assessed at Takeda for binding to the target protein at the molecular level, and approximately 11%*) of the compounds tested were confirmed to bind to the target protein. Takeda will proceed with further evaluation of the compounds based on the results.

*) It is generally recognized that hit rates of compounds against protein targets through computational drug design methods are well below 11%.

Contact:

Hirotsugu KOMATSU, Ph.D.

Interprotein Corporation

TEL/FAX: +81-(0)42-770-9477

E-mail:info@interprotein.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->